1 / 36

Who, What and When: Transplant for Acute Lymphoblastic Leukemia

Brandon Hayes-Lattin September 1 3 , 2013. Who, What and When: Transplant for Acute Lymphoblastic Leukemia. Indications for Hematopoietic Stem Cell Transplants in the United States, 2010 (Inflation factor: Auto=1.25 (80%), Allo =1.05 (95%), All Transplants). Number of Transplants.

zihna
Télécharger la présentation

Who, What and When: Transplant for Acute Lymphoblastic Leukemia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Brandon Hayes-Lattin September 13, 2013 Who, What and When: Transplant for Acute Lymphoblastic Leukemia

  2. Indications for Hematopoietic Stem Cell Transplants in the United States, 2010(Inflation factor: Auto=1.25 (80%), Allo=1.05 (95%), All Transplants) Number of Transplants Slide 8 SUM12_28.ppt

  3. ALL Survival SEER AYA Monograph, 2006

  4. “Myth of Second Remission” Forman and Rowe, Blood 2013;121:1077-1082

  5. Defining Role of Transplant in ALL • Consolidation • 75-90% of patients achieve complete remission • Relapse risk remains high • Potential benefit over chemotherapy • Myeloablativechemoradiotherapy • Graft-versus-Leukemia effect • Balance of risks • Early treatment-related toxicity • Late effects (GVHD)

  6. Predicting Risk

  7. Cytogenetic Risk(2008 WHO Classification) • Favorable • Hyperdiploidy (>50 chromosomes) • t(12;21) • ETV6-RUNX1 • Formerly TEL-AML • Unfavorable • Hypodiploidy (<44 chromosomes) • t(9;22) • BCR-ABL1 • Philadelphia chromosome • t(v;11q23) • MLL rearranged • t(4;11), t(9;11), t(11;19) • t(5;14) • IL3-IGH • t(1;19) • E2A-PBX1

  8. ALL Cytogenetics by Age Harrison CJ, Br J Haematol, 2008

  9. Hyper-CVAD

  10. Hyper-CVAD Good risk 0-1 5-year OS 62% Intermed risk 2-3 5-year OS 34% Poor risk 4-6 5-year OS 5%

  11. Minimal Residual Disease (16 week, GMALL) Overall survival p<0.0001 Only significant factor in multivariate analysis

  12. Novel Cytogenetic Abnormalities • Christine Harrison: advances in cytogenetic technology • Intrachromosomal amplification of chromosome 21 (iAMP21) • Multiple copies of RUNX1 • Older children/adolescents, present with low WBC, 5-year EFS 26% vs 83% Tricoli JV, JNCI, 2011. Harrison CJ, Br J Haematol, 2008

  13. Integrated Genomic Analysis AYA ALL • Charles Mullighan: B-cell precursors from patients in COG 9906, no known high-risk genetic alterations • Deletions and point mutations in IKZF1 (lymphoid transcription factor) • Increased risk of relapse HR 2.4 • Gene expression profiles similar to those of BCR-ABL1 patients • Resequencing found 11% with activating mutations in JAK1, JAK2, or JAK3 Tricoli JV, JNCI, 2011. Roberts, Cancer Cell, 2012

  14. Gene Expression Profiling in ALL • Cheryl Willman: 207 older children, high-risk (WBC >50), COG 9906 • 8 gene expression cluster groups • 2 associated with known cytogenetic abnormalites • 11q23 rearrangements MLL • t(1;19)E2a-PBX1 • 6 novel Zhang et al, Blood 2011

  15. Somatic alteration profiles Zhang et al, Blood, 2011

  16. Regimens

  17. Hyper CVAD

  18. R-Hyper-CVAD (CD20+, age <60) Rituximab 3-year OS 75% No rituximab 3-year OS 47%

  19. SURVIVAL: PEDIATRIC VS. ADULT REGIMENS Stock BLOOD 2008, pre-published online

  20. 100% FRALLE 93 (Pediatric) Age 15-20 Years (N = 77) 80% LALA 94 (Adult) 60% Age 15-20 Years (N = 100) Survival 40% France 20% 0% 0 1 2 3 4 5 6 Years 100% 100% DCOG 8599 (Pediatric) ALL97 (Pediatric) Age 15-18 Years (N = 47) 15-17 Years (N = 61) 75% 75% HO 8899 (Adult) Age 19-20 Years (N = 29) Survival Survival 50% 50% UKALLXII / E2993 (Adult) 15-17 Years (N = 67) Age 15-18 Years (N = 44) 25% 25% United Kingdom Netherlands 0% 0% 0 1 2 3 4 5 0 2 4 6 8 10 Years Years ALL age 15-21: Pediatric vs. Adult Therapy 100% CCG-1800 Series (Pediatric) 80% Age 16-21 Years (N = 175) 60% CALGB 8811-9511(Adult) EFS Age16-20 Years (N = 103) 40% 20-29 Years (N = 123) North America 20% 0% 0 2 4 6 8 10 Years

  21. ALL Survival: COG Chemotherapy Hunger et al. JCO 2012:20;1663-1669

  22. NCI Risk Classification at diagnosis (0232)

  23. High-Risk Therapy Based on AALL0232 (“PH” arm) • Induction • Prednisone x 28 days, age >10(increased osteonecrosis with dexamethasone) • Consolidation • Interim Maintenance #1 • High-dose methotrexate(5-year EFS 82% vs 75.4% with Capizzi methotrexate) • Delayed Intensification #1 • Slow Early Responders • Interim Maintenance #2 • Delayed Intensification #2 • Maintenance

  24. C10403: Intergroup ALL • Intergroup (CALGB, SWOG & ECOG) Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL) • Ages 16-39 years • Specific Aims • Improve outcome of AYAs with ALL • Evaluate efficacy and toxicity of this regimen in patients up to age 39 years • Evaluate adherence of medical oncologists to a “pediatric” ALL regimen • Assessment of Drug Delivery • vincristine, peg-asparaginase and methotrexate

  25. COG Risk Classification at diagnosis (1131)

  26. AALL1131: Very High-Risk • Induction • Consolidation • Control, OR • Arm 1: fractionated cyclophosphamide, etoposide, OR • Arm 2: clofarabine, fractionated cyclophosphamide, etoposide • MRD Flow: hypodiploidy or induction failure - option of SCT • Interim Maintenance #1 • Delayed Intensification • Control, OR • Arm 1: fractionated cyclophosphamide, etoposide, OR • Arm 2: clofarabine, fractionated cyclophosphamide, etoposide • Interim Maintenance #2 • Maintenance

  27. Allogeneic Transplant

  28. Allo Transplant Conditioning Regimen • Cyclophosphamide + 1200 cGy TBI • Children and Adolescents, Tracey et al. BBMT 2013;19:255-259 • Neither TBI >1200 cGy nor addition of etoposide improves survival

  29. Survival after HLA-identical Sibling Donor Transplants for ALL, Age < 20 yrs, 2000-2010- by Disease Status - 100 100 90 90 80 80 70 70 Early (N=849) 60 60 Probability of Survival, % 50 50 Intermediate (N=1,203) 40 40 30 30 20 20 Advanced (N=210) 10 10 P < 0.0001 0 0 1 3 0 2 4 5 6 Years Slide 30 SUM12_7.ppt

  30. Survival after HLA-identical Sibling Donor Transplants for ALL, Age ³ 20 yrs, 2000-2010- By Disease Status - 100 100 90 90 80 80 70 70 60 60 Early (N=2,214) Probability of Survival, % 50 50 40 40 Intermediate (N=715) 30 30 20 20 Advanced (N=584) 10 10 P < 0.0001 0 0 1 3 0 2 4 5 6 Years Slide 32 SUM12_9.ppt

  31. ASBMT Evidence-Based Review: Children • Matched related Allo • In CR1 for very high risk Ph+ patients • Equivalent to or better than chemo in remission beyond CR1 • MUD • Insufficient evidence • Auto • Insufficient evidence • Regimens • TBI-containing regimens are recommended ASBMT 2006

  32. ASBMT Evidence-Based Review: Adult ALL, updated 2012 • Changed • Myeloablativeallo age <35 in CR1 (all risk groups) • RIC allo may produce similar results • Unchanged • Allo over chemotherapy in CR2 • Allo over Auto • Related similar to unrelated donor • New • In absence of suitable donor, auto may be appropriate • In absence of suitable donor, cord blood by me appropriate • Imatinib before and/or after SCT for Ph+ ALL yields significantly superior survival ASBMT 2012

  33. Allo in CR1? • Gupta et al. Blood 2013;121:339-350 • Available sibling, or randomized auto vs chemo • 13 studies, N=2962, excluding Ph+ • Age <35 having matched sibling OR 0.79 (p=0.0003) • Age 35+ having matched sibling OR 1.01 • Auto vs chemo OR 1.18 (CI 0.99-1.41)

  34. OHSU Adult Regimen Guidelines • Age <30 • per COG AALL 0232 (PH) - no transplant • If unable to complete 0232 or other high risk features (Ph+, persistent diasease) move to allo transplant • Open COG AALL 1131 • Age 30-60 • hyper-CVAD - CR1 allogeneic SCT • R-hyper-CVAD - consider no CR1 allogeneic SCT • Age 60+ • hyper-CVAD (reduced cytarabine) - consider CR1 reduced intensity allogeneic SCT • R-hyper-CVAD (reduced cytarabine) - consider CR1 reduced intensity allogeneic SCT • EWALL

More Related